{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:57:34Z","timestamp":1790773054410,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-026-02390-z","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:45:23Z","timestamp":1783305923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness of quadruple oral hypoglycemic therapy in type 2 diabetes patients refusing insulin therapy"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6896-9024","authenticated-orcid":false,"given":"Han-Sang","family":"Baek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-2278","authenticated-orcid":false,"given":"Chaiho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5135-3290","authenticated-orcid":false,"given":"Tae-Seo","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8841-523X","authenticated-orcid":false,"given":"Hyun Shik","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"10365","key":"2390_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400(10365):1803\u201320.","journal-title":"Lancet"},{"issue":"1","key":"2390_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3803\/EnM.2022.105","volume":"37","author":"J Yu","year":"2022","unstructured":"Yu J, Lee S-H, Kim MK. Recent updates to clinical practice guidelines for diabetes mellitus. Endocrinol Metab (Seoul). 2022;37(1):26\u201337.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"4","key":"2390_CR3","doi-asserted-by":"publisher","first-page":"518","DOI":"10.4093\/dmj.2024.0087","volume":"48","author":"C-N Kim","year":"2024","unstructured":"Kim C-N, Jung Y-S, Kim Y-E, Ock M, Yoon S-J. Korean National Burden of Disease: The Importance of Diabetes Management. Diabetes Metab J. 2024;48(4):518\u201330.","journal-title":"Diabetes Metab J"},{"issue":"1","key":"2390_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3803\/EnM.2023.1816","volume":"39","author":"JY Kim","year":"2024","unstructured":"Kim JY, Kim NH. Initial Combination Therapy in Type 2 Diabetes. Endocrinol Metab (Seoul). 2024;39(1):23\u201332.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2390_CR5","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.jcjd.2017.10.034","volume":"42","author":"L Lipscombe","year":"2018","unstructured":"Lipscombe L, Booth G, Butalia S, Dasgupta K, Eurich DT, Goldenberg R, Khan N, MacCallum L, Shah BR, Simpson S. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. Can J Diabetes. 2018;42:S88\u2013103.","journal-title":"Can J Diabetes"},{"issue":"3","key":"2390_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/dom.12417","volume":"17","author":"MA Abdul-Ghani","year":"2015","unstructured":"Abdul-Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, DeFronzo RA. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab. 2015;17(3):268\u201375.","journal-title":"Diabetes Obes Metab"},{"issue":"Supplement1","key":"2390_CR7","first-page":"S158","volume":"47","author":"ADAPP Committee","year":"2024","unstructured":"Committee ADAPP. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142024. Diabetes Care. 2024;47(Supplement1):S158\u201378.","journal-title":"Diabetes Care"},{"issue":"3","key":"2390_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2337\/dc14-1142","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38(3):376\u201383.","journal-title":"Diabetes Care"},{"issue":"3","key":"2390_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3803\/EnM.2023.1688","volume":"38","author":"BW Lee","year":"2023","unstructured":"Lee BW, Min K, Hong EG, Ku BJ, Kang JG, Chon S, Lee WY, Park MK, Kim JH, Kim SY, et al. Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION). Endocrinol Metab (Seoul). 2023;38(3):328\u201337.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2390_CR10","doi-asserted-by":"crossref","unstructured":"Kim HJ, Noh JH, Moon MK, Choi SH, Ko SH, Rhee EJ, Hur KY, Jeong IK. A multicenter, randomized, open-label study to compare the effects of gemigliptin add-on or escalation of metformin dose on glycemic control and safety in patients with inadequately controlled type 2 diabetes mellitus treated with metformin and SGLT-2 inhibitors (SO GOOD study). J Diabetes Res. 2024;2024(2314\u20136753 (Electronic)):8915591.","DOI":"10.1155\/2024\/8915591"},{"issue":"6","key":"2390_CR11","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/dom.14679","volume":"24","author":"M Lee","year":"2022","unstructured":"Lee M, Lee W-j, Kim JH, Lee B-W. Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study. Diabetes Obes Metab. 2022;24(6):1105\u201313.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2390_CR12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/dme.14260","volume":"37","author":"A Turchin","year":"2020","unstructured":"Turchin A, Hosomura N, Zhang H, Malmasi S, Shubina M. Predictors and consequences of declining insulin therapy by individuals with type 2 diabetes. Diabet Med. 2020;37(5):814\u201321.","journal-title":"Diabet Med"},{"issue":"10","key":"2390_CR13","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2337\/dc09-0653","volume":"32","author":"I Lingvay","year":"2009","unstructured":"Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams-Huet B, Raskin P. Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes: Which is better? Diabetes Care. 2009;32(10):1789\u201395.","journal-title":"Diabetes Care"},{"issue":"2","key":"2390_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2310\/6650.2007.06036","volume":"55","author":"I Lingvay","year":"2007","unstructured":"Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes: Effective, safe, and well accepted. J Invest Med. 2007;55(2):62\u20138.","journal-title":"J Invest Med"},{"issue":"9","key":"2390_CR15","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s13300-023-01437-x","volume":"14","author":"EJ Ku","year":"2023","unstructured":"Ku EJ, Oh TK. Long-Term Effectiveness of Quadruple Combination Therapy with Empagliflozin Versus Basal Long-Acting Insulin Therapy in Patients with Type 2 Diabetes: 3-Year Retrospective Observational Study. Diabetes Ther. 2023;14(9):1471\u20139.","journal-title":"Diabetes Ther"},{"issue":"5","key":"2390_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.4093\/dmj.2020.0107","volume":"45","author":"JS Moon","year":"2021","unstructured":"Moon JS, Suh S, Kim SS, Jin HY, Kim JM, Jang MH, Lee KA, Lee JH, Chung SM, Lyu YS, et al. Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study. Diabetes Metab J. 2021;45(5):675\u201383.","journal-title":"Diabetes Metab J"},{"issue":"Supplement2","key":"2390_CR17","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.2337\/dcS15-3023","volume":"39","author":"F Giorgino","year":"2016","unstructured":"Giorgino F, Home PD, Tuomilehto J. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear? Diabetes Care. 2016;39(Supplement2):S187\u201395.","journal-title":"Diabetes Care"},{"issue":"10","key":"2390_CR18","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2337\/dc20-2439","volume":"44","author":"M Lind","year":"2021","unstructured":"Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes Care. 2021;44(10):2231\u20137.","journal-title":"Diabetes Care"},{"issue":"6","key":"2390_CR19","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2337\/dc19-1817","volume":"43","author":"J Tian","year":"2020","unstructured":"Tian J, Ohkuma T, Cooper M, Harrap S, Mancia G, Poulter N, Wang J-G, Zoungas S, Woodward M, Chalmers J. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial. Diabetes Care. 2020;43(6):1293\u20139.","journal-title":"Diabetes Care"},{"issue":"3","key":"2390_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2337\/dc17-1144","volume":"42","author":"N Laiteerapong","year":"2018","unstructured":"Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, Karter AJ. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2018;42(3):416\u201326.","journal-title":"Diabetes Care"},{"issue":"9","key":"2390_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41574-021-00512-2","volume":"17","author":"S Bellary","year":"2021","unstructured":"Bellary S, Kyrou I, Brown JE, Bailey CJ. Type 2 diabetes mellitus in older adults: clinical considerations and management. Nat Rev Endocrinol. 2021;17(9):534\u201348.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2390_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4093\/dmj.2023.0041","volume":"47","author":"S-H Ko","year":"2023","unstructured":"Ko S-H, Han KD, Park Y-M, Yun J-S, Kim K, Bae J-H, Kwon H-S, Kim N-H. Diabetes Mellitus in the Elderly Adults in Korea: Based on Data from the Korea National Health and Nutrition Examination Survey 2019 to 2020. Diabetes Metab J. 2023;47(5):643\u201352.","journal-title":"Diabetes Metab J"},{"issue":"4","key":"2390_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4093\/dmj.2024.0310","volume":"48","author":"J-S Yun","year":"2024","unstructured":"Yun J-S, Kim K, Ahn Y-B, Han K, Ko S-H. Holistic and Personalized Strategies for Managing in Elderly Type 2 Diabetes Patients. Diabetes Metab J. 2024;48(4):531\u201345.","journal-title":"Diabetes Metab J"},{"issue":"5","key":"2390_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3803\/EnM.2023.1765","volume":"38","author":"J Lee","year":"2023","unstructured":"Lee J, Kim H-S, Song K-H, Yoo SJ, Han K, Lee S-H. Risk of cause-specific mortality across glucose spectrum in elderly people: a nationwide population-based cohort study. Endocrinol Metab (Seoul). 2023;38(5):525.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"4","key":"2390_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3803\/EnM.2022.1501","volume":"37","author":"HS Baek","year":"2022","unstructured":"Baek HS, Park JY, Yu J, Lee J, Yang Y, Ha J, Lee SH, Cho JH, Lim DJ, Kim HS. Characteristics of Glycemic Control and Long-Term Complications in Patients with Young-Onset Type 2 Diabetes. Endocrinol Metab (Seoul). 2022;37(4):641\u201351.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"5","key":"2390_CR26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3904\/kjim.2021.379","volume":"36","author":"YS Yang","year":"2021","unstructured":"Yang YS, Han K, Sohn TS, Kim NH. Young-onset type 2 diabetes in South Korea: a review of the current status and unmet need. Korean J Intern Med. 2021;36(5):1049.","journal-title":"Korean J Intern Med"},{"issue":"12","key":"2390_CR27","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S2213-8587(14)70137-8","volume":"2","author":"RO Yeung","year":"2014","unstructured":"Yeung RO, Zhang Y, Luk A, Yang W, Sobrepena L, Yoon KH, Aravind SR, Sheu W, Nguyen TK, Ozaki R, et al. Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. Lancet Diabetes Endocrinol. 2014;2(12):935\u201343.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2390_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/dom.12825","volume":"19","author":"D Li","year":"2017","unstructured":"Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co\u2010transporter 2 inhibitors: a meta\u2010analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348\u201355.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2390_CR29","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/dom.13130","volume":"20","author":"GP Fadini","year":"2018","unstructured":"Fadini GP, Bonora BM, Mayur S, Rigato M, Avogaro A. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium\u2010glucose co\u2010transporter\u20102 inhibitors. Diabetes Obes Metab. 2018;20(3):740\u20134.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2390_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.diabet.2018.01.011","volume":"44","author":"YK Cho","year":"2018","unstructured":"Cho YK, Kang YM, Lee SE, Lee J, Park JY, Lee WJ, Kim YJ, Jung CH. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2018;44(5):393\u2013401.","journal-title":"Diabetes Metab"},{"issue":"6","key":"2390_CR31","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.4093\/dmj.2024.0036","volume":"48","author":"H-S Baek","year":"2024","unstructured":"Baek H-S, Jeong C, Yang Y, Lee J, Lee J, Lee S-H, Cho JH, Sohn T-S, Son H-S, Yoon K-H, et al. Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights. Diabetes Metab J. 2024;48(6):1169\u201375.","journal-title":"Diabetes Metab J"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02390-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02390-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02390-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:03:46Z","timestamp":1790769826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02390-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2390"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02390-z","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study\u2019s data were approved by the Catholic University Data Review Committee, with all information anonymized. Given the retrospective cohort study design, there was no risk of physical or mental harm to patients. Consequently, the review board waived the requirement for informed consent. This study complied with the principles of the Declaration of Helsinki and received approval from the Institutional Review Board of Uijeongbu St. Mary\u2019s Hospital (UC24RISI0077).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"295"}}